Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Mercedes Salgado Fernández"'
Autor:
Nieves Martínez-Lago, Ana Fernández-Montes, Marta Covela, Elena M. Brozos, Juan De la Cámara, José C. Méndez Méndez, Mónica Jorge-Fernández, Antía Cousillas Castiñeiras, Cristina Reboredo, David Arias Ron, María L. Pellón Augusto, Paula González Villarroel, Begoña Graña, Mercedes Salgado Fernández, Alberto Carral Maseda, Francisca Vázquez Rivera, Sonia Candamio Folgar, Margarita Reboredo López, On behalf of the Galician Research Group on Digestive Tumors (GITuD)
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of
Externí odkaz:
https://doaj.org/article/0205a0ed5fdf486f96be2430c7159205
Autor:
David Arias Ron, Carmen M. Labandeira, Soledad Cameselle García, Jesús García Mata, Mercedes Salgado Fernández
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 69-75 (2020)
In a patient who had been diagnosed in 2006 with appendiceal adenocarcinoma with peritoneal metastases after an incomplete surgery, palliative chemotherapy was administered. First-line treatment with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX
Externí odkaz:
https://doaj.org/article/16e9115873894ca895238c1f37720e24
Autor:
Nieves Martínez-Lago, Soledad Cameselle García, Beatriz Alonso de Castro, Martín I. Gómez-Randulfe Rodríguez, Marta Carmona Campos, Paula González Villarroel, Mercedes Salgado Fernández, Juan C. De la Cámara Gómez, Carlos Romero Reinoso, Antía Cousillas Castiñeiras, José Carlos Méndez Méndez, Yolanda Vidal Insua, Ana Fernández-Montes
Publikováno v:
PLoS ONE, Vol 17, Iss 6 (2022)
Background The VELOUR study showed the benefit of FOLFIRI-Aflibercept (FA) versus FOLFIRI in patients with metastatic colorectal cancer (mCRC) in second-line treatment. However, only 36% of the included patients were ≥65 years. Thus, we seek to eva
Externí odkaz:
https://doaj.org/article/e00901a0b5b7464ca871c78422a4ada3
Autor:
Silvia García Adrián, Adán Rodríguez González, Eva Martínez de Castro, Vanessa Pachón Olmos, Laura Ortega Morán, Purificación Martínez del Prado, Mercedes Salgado Fernández, José David Cumplido Burón, Ignacio García Escobar, Joaquina Martínez Galán, Ana Isabel Ferrer Pérez, Fernando Neria, Diego Cacho Lavin, Borja López de San Vicente Hernández, Paula Jiménez-Fonseca, Andrés J. Muñoz Martín
Publikováno v:
European Journal of Internal Medicine. 105:30-37
Background Pancreatic carcinoma is one of the tumors associated with a higher risk for thromboembolic events, with incidence rates ranging from 5% to 41% in previous retrospective series. Patients and methods We conducted a retrospective study in ele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49cacca2eacab8c10ac6de70f8d57bc7
https://doi.org/10.1016/j.ejim.2022.07.020
https://doi.org/10.1016/j.ejim.2022.07.020
Autor:
Soledad Cameselle Garcia, Mercedes Salgado Fernández, Jesús García Mata, David Arias Ron, Carmen M. Labandeira
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 13, Iss 1, Pp 69-75 (2020)
Case Reports in Oncology, Vol 13, Iss 1, Pp 69-75 (2020)
In a patient who had been diagnosed in 2006 with appendiceal adenocarcinoma with peritoneal metastases after an incomplete surgery, palliative chemotherapy was administered. First-line treatment with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::857a8a7dbd9c2aecc7e885d9f5fe40c7
https://doi.org/10.1159/000505237
https://doi.org/10.1159/000505237
Autor:
Nieves Martínez-Lago, Soledad Cameselle García, Beatriz Alonso de Castro, Martín I. Gómez-Randulfe Rodríguez, Marta Carmona Campos, Paula González Villarroel, Mercedes Salgado Fernández, Juan C. De la Cámara Gómez, Carlos Romero Reinoso, Antía Cousillas Castiñeiras, José Carlos Méndez Méndez, Yolanda Vidal Insua, Ana Fernández-Montes
Publikováno v:
PloS one. 17(6)
Background The VELOUR study showed the benefit of FOLFIRI-Aflibercept (FA) versus FOLFIRI in patients with metastatic colorectal cancer (mCRC) in second-line treatment. However, only 36% of the included patients were ≥65 years. Thus, we seek to eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeaaf1c74f10bfe501df8239567e0e09
https://pubmed.ncbi.nlm.nih.gov/35657983
https://pubmed.ncbi.nlm.nih.gov/35657983
Autor:
Mónica Jorge Fernández, Maria Luz Pellon Augusto, J. Méndez, Ana Montes, Juan de la Cámara Gómez, Mercedes Salgado Fernández, Margarita Reboredo Lopez, Nieves Martinez Lago, Guillermo Alfonso Quintero Aldana, Paula González Villaroel, Marta Covela Rúa, Jesús García Gómez, Begoña Graña Suárez
Publikováno v:
Cancer Medicine
Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without bevacizumab versus placebo. The effect of FOLFIRI‐afliber
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae65e3bd50f9a60867938d42f4c8e9d0
http://europepmc.org/articles/PMC6434192
http://europepmc.org/articles/PMC6434192
Autor:
Nieves Martinez Lago, Ana Fernández Montes, Marta Covela Rúa, Elena M. Brozos Vázquez, Juan C. De la Cámara Gómez, Jose C. Méndez Méndez, Mónica Jorge Fernández, Antía Cousillas Castiñeiras, Cristina Reboredo Rendo, David Arias Ron, Marta Carmona Campos, Yolanda Vidal Insua, Maria L. Pellón Augusto, Paula González Villarroel, Begoña Graña Suarez, Mercedes Salgado Fernández, Alberto Carral Maseda, Francisca Vázquez Rivera, Sonia Candamio Folgar, Margarita Reboredo López
Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of antiangi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4516fdfd7ed86ceeb492a6f2d08d1f56
https://doi.org/10.21203/rs.3.rs-79440/v1
https://doi.org/10.21203/rs.3.rs-79440/v1
Autor:
Carlos Romero Reinoso, Paula Gonzalez Villarroel, Juan de la Cámara Gómez, Ana Montes, Mónica Jorge Fernández, Jose Carlos Mendez, Manuel Valladares Ayerbes, Margarida Reboredo López, Mari Luz Pellón Augusto, Mercedes Salgado Fernández, Manuel Ramos Vázquez, Guillermo Alfonso Quintero Aldana, Marta Covela Rúa
Publikováno v:
Journal of geriatric oncology. 11(8)
Background Despite the high morbidity and mortality of metastatic colorectal cancer (mCRC) in older patients, they have been underrepresented in clinical trials and their optimal treatment is yet to be determined. This open-label phase II study evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd82eb8a09073d05b0cb643d8f487b23
https://pubmed.ncbi.nlm.nih.gov/34507891
https://pubmed.ncbi.nlm.nih.gov/34507891
Autor:
Mercedes Salgado Fernández, Bruno Bockorny, Carmen Guillén-Ponce, Ravit Geva, Abi Vainstein-Haras, Debby Ickowicz, Teresa Macarulla, Andrés Muñoz, Jaime Feliu, David Gutierrez Abad, Valerya Semenisty, Paul E. Oberstein, Angela Tatiana Alistar, Liron Shemesh-Darvish, Irit Glicko-Kabir, Erkut Borazanci, Ella Sorani, Amnon Peled, Shaul Kadosh, Mariano Ponz-Sarvise, Marya F. Chaney, Manuel Hidalgo
Publikováno v:
Cancer Research. 81:CT177-CT177
Background: Improving outcomes of PDAC with checkpoint inhibitors (CPIs) have been ineffective, underscoring the need to co-target alternative pathways. Preclinical data showed that CXCR4-SDF1 axis modulates the tumor microenvironment (TME) in PDAC a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff812b09702bb4affd5a57eb03966e83
https://doi.org/10.1158/1538-7445.am2021-ct177
https://doi.org/10.1158/1538-7445.am2021-ct177